Discover
MBRX
Moleculin Biotech, Inc.
2.69
7 x 2.55
2 x 3.27
bid
ask
-
0.10
3.58%
5 @ 04:00 PM
2.51 -0.18 (6.68%)
| Ytd | -18.73% | |
| 1y | -69.08% |
2.53
day range
2.75
1.79
52 week range
24.00
| Open | 2.59 | Prev Close | 2.79 | Low | 2.53 | High | 2.75 | Mkt Cap | 14.35M |
| Vol | 664.37K | Avg Vol | 495.83K | EPS | -16.16 | P/E | N/A | Forward P/E | -0.29 |
| Beta | 1.86 | Short Ratio | 0.36 | Inst. Own | 15.34% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-08 | 50-d Avg | 2.58 | 200-d Avg | 5.44 | 1yr Est | 18.00 |
| Income Statement | |||
| Operating Expenses | 7.87M | ||
| Research and Development Expense | 5.38M | ||
| Selling, General and Administrative Expense | 2.49M | ||
| Operating Income | -7.87M | ||
| Net Income | -12.84M | ||
| Net Income Common Stock | -14.61M | ||
| Net Income Common Stock (USD) | -14.61M | ||
| Consolidated Income | -12.84M | ||
| Earnings per Basic Share | -3.54 | ||
| Earnings per Basic Share (USD) | -3.54 | ||
| Earnings per Diluted Share | -3.54 | ||
| Earning Before Interest & Taxes (EBIT) | -12.84M | ||
| Earning Before Interest & Taxes (USD) | -12.84M | ||
| Preferred Dividends Income Statement Impact | 1.77M | ||
| Weighted Average Shares | 4.12M | ||
| Weighted Average Shares Diluted | 4.12M | ||
| Balance Sheet | |||
| Cash and Equivalents | 10.32M | ||
| Cash and Equivalents (USD) | 10.32M | ||
| Current Assets | 10.96M | ||
| Property, Plant & Equipment Net | 354.00K | ||
| Total Assets | 23.36M | ||
| Total Debt | 185.00K | ||
| Current Liabilities | 7.96M | ||
| Debt Non-Current | 185.00K | ||
| Total Liabilities | 8.18M | ||
| Accumulated Retained Earnings (Deficit) | -218.85M | ||
| Accumulated Other Comprehensive Income | -52.00K | ||
| Shareholders Equity | 15.18M | ||
| Shareholders Equity (USD) | 15.18M | ||
| Assets Non-Current | 12.40M | ||
| Total Debt (USD) | 185.00K | ||
| Goodwill and Intangible Assets | 11.15M | ||
| Liabilities Non-Current | 218.00K | ||
| Trade and Non-Trade Payables | 4.57M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 8.00K | ||
| Net Cash Flow from Financing | 7.61M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 1.44M | ||
| Issuance (Purchase) of Equity Shares | 7.61M | ||
| Net Cash Flow from Operations | -6.11M | ||
| Effect of Exchange Rate Changes on Cash | -62.00K | ||
| Share Based Compensation | 380.00K | ||